

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-15 (Cancelled).

16(Previously presented). An isolated peptide selected from the group consisting of SEQ ID NOS: 35, 36, 37, 38, 39, 40, and 41.

Claims 17-54 (Cancelled).

55(Previously presented). The isolated peptide according to claim 16, consisting of SEQ ID NO:38.

56(Previously presented). The isolated peptide according to claim 16, consisting of SEQ ID NO:39.

57(Previously presented). The isolated peptide according to claim 16, consisting of SEQ ID NO:41.

58(Previously presented). An isolated peptide consisting of 9 or 10 contiguous amino acid residues that appear in the sequence of human Lactadherin (BA-46) consisting of SEQ ID NO:78, which said isolated peptide promotes effective binding to a MHC class 1 type molecule so as to elicit a CTL response.